{"id":"W2125877270","doi":"10.1158/1078-0432.ccr-11-3007","title":"A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Adverse effect; Tolerability; Dosing; Multiple myeloma; Pharmacokinetics; Proteasome inhibitor; Pharmacology; Refractory (planetary science); Internal medicine; Oncology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001224576,0.002249961,0.002892472,0.0006024282,0.0004950213,0.0008955069,0.001199199,0.001572168,0.002369362],"category_scores_gemma":[0.0008349479,0.0007231688,0.001172868,0.0005070285,0.001344695,0.0008200196,0.0003137615,0.003965084,0.0007243686],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001190099,"about_ca_system_score_gemma":0.001793381,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001114427,"about_ca_topic_score_gemma":0.002340756,"domain_scores_codex":[0.9994597,0.0002027782,0.00002084736,0.0001239491,0.00006307889,0.0001297288],"domain_scores_gemma":[0.9993316,0.00008647536,0.0001289177,0.0000867951,0.00004017372,0.0003260914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6215266,0.1617269,0.005021265,0.001045137,0.00137542,0.0003972742,0.0004379473,0.004322605,0.1047991,0.0002813739,0.003035588,0.0960308],"study_design_scores_gemma":[0.3932737,0.5920065,0.006391386,0.00001630396,0.0002348412,0.0001691459,0.00002767025,0.0008549566,0.005449124,0.00008015845,0.001469932,0.00002619857],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930326,0.001482821,0.0005915787,0.00024414,0.0001062604,0.003038354,0.0004748436,0.0001187951,0.0009105819],"genre_scores_gemma":[0.9900858,0.001357341,0.001862576,0.0005004552,0.0001864371,0.003288901,0.001104439,0.00002982633,0.001584187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002892472,"threshold_uncertainty_score":0.008634806,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2172473456305167,"score_gpt":0.4730811051271257,"score_spread":0.255833759496609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}